175 related articles for article (PubMed ID: 12846942)
1. Treatment of Irritable Bowel Syndrome.
Spiller RC
Curr Treat Options Gastroenterol; 2003 Aug; 6(4):329-337. PubMed ID: 12846942
[TBL] [Abstract][Full Text] [Related]
2. Current gut-directed therapies for irritable bowel syndrome.
Chang HY; Kelly EC; Lembo AJ
Curr Treat Options Gastroenterol; 2006 Jul; 9(4):314-23. PubMed ID: 16836950
[TBL] [Abstract][Full Text] [Related]
3. Tegaserod for the treatment of irritable bowel syndrome and chronic constipation.
Evans BW; Clark WK; Moore DJ; Whorwell PJ
Cochrane Database Syst Rev; 2007 Oct; (4):CD003960. PubMed ID: 17943807
[TBL] [Abstract][Full Text] [Related]
4. Novel Therapies in IBS-D Treatment.
Nee J; Zakari M; Lembo AJ
Curr Treat Options Gastroenterol; 2015 Dec; 13(4):432-40. PubMed ID: 26432092
[TBL] [Abstract][Full Text] [Related]
5. A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome.
Camilleri M; Chey WY; Mayer EA; Northcutt AR; Heath A; Dukes GE; McSorley D; Mangel AM
Arch Intern Med; 2001 Jul; 161(14):1733-40. PubMed ID: 11485506
[TBL] [Abstract][Full Text] [Related]
6. [Management of irritable bowel syndrome].
Choi MG
Korean J Gastroenterol; 2006 Feb; 47(2):125-30. PubMed ID: 16498278
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of current drug therapies in irritable bowel syndrome: what works and does not work.
Schoenfeld P
Gastroenterol Clin North Am; 2005 Jun; 34(2):319-35, viii. PubMed ID: 15862938
[TBL] [Abstract][Full Text] [Related]
8. [Guidelines for the treatment of irritable bowel syndrome].
Kwon JG; Park KS; Park JH; Park JM; Park CH; Lee KJ; Park HJ; Rhee JC;
Korean J Gastroenterol; 2011 Feb; 57(2):82-99. PubMed ID: 21350320
[TBL] [Abstract][Full Text] [Related]
9. Targeted therapies for diarrhea-predominant irritable bowel syndrome.
Olden KW
Clin Exp Gastroenterol; 2012; 5():69-100. PubMed ID: 22754282
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic and therapeutic strategies in the irritable bowel syndrome.
Cremonini F; Talley NJ
Minerva Med; 2004 Oct; 95(5):427-41. PubMed ID: 15467518
[TBL] [Abstract][Full Text] [Related]
11. Tegaserod for the treatment of irritable bowel syndrome.
Evans BW; Clark WK; Moore DJ; Whorwell PJ
Cochrane Database Syst Rev; 2004; (1):CD003960. PubMed ID: 14974049
[TBL] [Abstract][Full Text] [Related]
12. Pharmacologic therapy for the irritable bowel syndrome.
Talley NJ
Am J Gastroenterol; 2003 Apr; 98(4):750-8. PubMed ID: 12738451
[TBL] [Abstract][Full Text] [Related]
13. Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome.
Lembo T; Wright RA; Bagby B; Decker C; Gordon S; Jhingran P; Carter E;
Am J Gastroenterol; 2001 Sep; 96(9):2662-70. PubMed ID: 11569692
[TBL] [Abstract][Full Text] [Related]
14. Irritable bowel syndrome: a mild disorder; purely symptomatic treatment.
Prescrire Int; 2009 Apr; 18(100):75-9. PubMed ID: 19585728
[TBL] [Abstract][Full Text] [Related]
15. Effect of alosetron on bowel urgency and global symptoms in women with severe, diarrhea-predominant irritable bowel syndrome: analysis of two controlled trials.
Lembo AJ; Olden KW; Ameen VZ; Gordon SL; Heath AT; Carter EG
Clin Gastroenterol Hepatol; 2004 Aug; 2(8):675-82. PubMed ID: 15290660
[TBL] [Abstract][Full Text] [Related]
16. A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS.
Chang L; Ameen VZ; Dukes GE; McSorley DJ; Carter EG; Mayer EA
Am J Gastroenterol; 2005 Jan; 100(1):115-23. PubMed ID: 15654790
[TBL] [Abstract][Full Text] [Related]
17. Management of the irritable bowel syndrome.
Camilleri M
Gastroenterology; 2001 Feb; 120(3):652-68. PubMed ID: 11179242
[TBL] [Abstract][Full Text] [Related]
18. Episodic nature of symptoms in irritable bowel syndrome.
Palsson OS; Baggish J; Whitehead WE
Am J Gastroenterol; 2014 Sep; 109(9):1450-60. PubMed ID: 24980882
[TBL] [Abstract][Full Text] [Related]
19. Development of the Diary for Irritable Bowel Syndrome Symptoms to Assess Treatment Benefit in Clinical Trials: Foundational Qualitative Research.
Fehnel SE; Ervin CM; Carson RT; Rigoni G; Lackner JM; Coons SJ;
Value Health; 2017 Apr; 20(4):618-626. PubMed ID: 28408004
[TBL] [Abstract][Full Text] [Related]
20. Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome.
Chey WD; Chey WY; Heath AT; Dukes GE; Carter EG; Northcutt A; Ameen VZ
Am J Gastroenterol; 2004 Nov; 99(11):2195-203. PubMed ID: 15555002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
